Blueberries Medical Corp.: directors' dealings · Canada · SEDI

About Blueberries Medical Corp.

Blueberries Medical Corp. is a Canadian-listed company with a history on the Canadian junior markets, associated with the CSE/TSX Venture ecosystem under the BBM symbol, while its operating footprint is primarily in Colombia. For French-speaking investors in Europe and Canada, it is best understood as a cannabis-medical and cannabis-derived-ingredients story with Latin American exposure, meaningful regulatory complexity, and an export-oriented commercial model. The company states that it holds the licenses required by the relevant Colombian ministries to produce, process, and commercialize cannabis products with different THC profiles, and that its core operations are centered in the Bogotá Savannah area of central Colombia. Blueberries Medical’s roots trace back to the 2019 business combination between CDN MSolar and Blueberries Cannabis Corp., which created Blueberries Medical Corp. and brought the business onto Canadian public markets. Since then, the company has positioned itself as a Latin American producer of medicinal cannabis and cannabis-derived products. Its operating model is vertically integrated and built around cultivation, extraction, standardization, formulation, and commercialization. The company’s current portfolio emphasizes dried-flower extraction, non-psychoactive ingredients, water-soluble CBD, THC resin and distillate, compounded formulations, CBD/THC flower, and use cases spanning food, wellness, cosmetics, and therapeutic applications. From a competitive standpoint, Blueberries aims to leverage scientific know-how, production cost advantages, and distribution agreements to serve as an international supplier of cannabis-derived ingredients across multiple end markets. The business nevertheless remains a niche operator in a highly regulated and still-developing industry, with execution risk tied to production scale-up, compliance, channel development, and customer adoption. Recent company disclosures indicate a continued push toward product diversification beyond the core cannabis platform, including a first commercial sale to a domestic veterinary medicine laboratory in April 2025, which suggests an effort to broaden the revenue base and increase the commercial relevance of its extraction and formulation capabilities. Geographically, the company remains anchored in Colombia while pursuing regional and international markets. Its recent disclosures through SEDAR+ and corporate communications point to ongoing product development, commercialization efforts, and strategic partnerships intended to extend the platform beyond a pure raw-material model. For TSX/TSXV investors in Canada, the equity case is primarily tied to the company’s ability to convert licensed Colombian production assets into repeatable sales, secure regulatory-compliant market access, and build a more diversified portfolio of cannabis-related and adjacent health products. In short, Blueberries Medical is a small-cap specialty health and cannabis platform with international ambitions, but one that still requires disciplined execution to translate operational capabilities into sustainable profitability.